Universal Beteiligungs und Servicegesellschaft mbH cut its stake in shares of Avantor, Inc. (NYSE:AVTR – Free Report) by 57.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 163,708 shares of the company’s stock after selling 216,587 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Avantor were worth $2,043,000 as of its most recent SEC filing.
Other institutional investors also recently bought and sold shares of the company. Dodge & Cox lifted its stake in shares of Avantor by 17.1% in the 2nd quarter. Dodge & Cox now owns 117,433,484 shares of the company’s stock worth $1,580,655,000 after acquiring an additional 17,170,761 shares during the period. Norges Bank purchased a new position in Avantor during the second quarter worth about $108,167,000. Engine Capital Management LP acquired a new stake in Avantor in the second quarter valued at about $74,088,000. Clarkston Capital Partners LLC boosted its holdings in Avantor by 45.8% in the 2nd quarter. Clarkston Capital Partners LLC now owns 13,982,090 shares of the company’s stock valued at $188,199,000 after purchasing an additional 4,390,140 shares in the last quarter. Finally, Invesco Ltd. boosted its holdings in Avantor by 36.5% in the 2nd quarter. Invesco Ltd. now owns 15,933,860 shares of the company’s stock valued at $214,470,000 after purchasing an additional 4,264,449 shares in the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.
Avantor Price Performance
Avantor stock opened at $10.81 on Friday. The firm has a market capitalization of $7.37 billion, a PE ratio of -83.15, a P/E/G ratio of 3.83 and a beta of 0.93. Avantor, Inc. has a 52 week low of $10.62 and a 52 week high of $22.73. The firm’s 50-day simple moving average is $11.59 and its 200 day simple moving average is $12.43. The company has a quick ratio of 0.96, a current ratio of 1.49 and a debt-to-equity ratio of 0.65.
Analyst Upgrades and Downgrades
Several analysts have recently commented on the company. Bank of America cut Avantor from a “buy” rating to a “neutral” rating and set a $13.00 price target for the company. in a report on Monday, December 15th. Raymond James Financial downgraded Avantor from an “outperform” rating to a “market perform” rating in a report on Tuesday, November 4th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $12.00 price target (down from $14.00) on shares of Avantor in a research note on Thursday, October 30th. UBS Group set a $12.00 price objective on shares of Avantor in a research note on Thursday, October 30th. Finally, Robert W. Baird upped their target price on shares of Avantor from $15.00 to $17.00 and gave the stock an “outperform” rating in a research report on Friday, October 24th. Three analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $13.60.
View Our Latest Report on AVTR
Insider Transactions at Avantor
In related news, Director Sanjeev K. Mehra bought 350,000 shares of Avantor stock in a transaction that occurred on Friday, December 5th. The shares were purchased at an average price of $11.09 per share, with a total value of $3,881,500.00. Following the purchase, the director owned 350,000 shares in the company, valued at $3,881,500. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 1.20% of the company’s stock.
Avantor Profile
Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.
Avantor’s offerings are organized across two primary segments.
Further Reading
- Five stocks we like better than Avantor
- Trump’s NEW Executive Order – BIG Changes Coming to Retirement Accounts
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- New Banking Law #1582 Could Unlock $21 Trillion for Americans
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.
